Particle.news
Download on the App Store

Guardant Health Shares Hit Record High on Earnings Beat and Raised Sales Guidance

The precision oncology company lifted its full-year revenue target to $965 million to $970 million after posting $265 million in quarterly sales.

Overview

  • Shares jumped 27.87% on Thursday, reaching an intraday peak of $95.88 before closing at $92.41.
  • Quarterly revenue rose 38.7% year over year to $265 million from $191 million.
  • Net loss narrowed 13.9% to $92.7 million compared with the same period last year.
  • Management raised full-year revenue guidance from $915–$925 million to $965–$970 million, implying roughly 31% growth versus 2024.
  • Results were described as strong across all business lines, while some media coverage paired the news with unrelated promotional stock pitches.